Individual risk of inflammation
If the clinical parameters are persistently poor despite a marked reduction in the numbers of bacteria, an analysis of the individual risk of inflammation with GenoType IL-1 is recommended at this point if not before. Because the immune system of patients with interleukin-1 gene mutations can be very sensitive even to small quantities of bacteria. In the presence of a genetic predisposition, the treatment is adapted to the patient’s risk profile, e.g. by shortening the recall intervals. Unlike a marker bacteria analysis, human genetic testing only has to be carried out once in a person’s lifetime, because a person’s genetic background does not change.